Hello,
Welcome to our flagship newsletter, MarketBeat Daily Ratings.
We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.
But first, we need you to do two quick things:
1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.
2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report.
Confirm your subscription here.
After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.
Thank you again for subscribing. We look forward to being an important part of your investing journey
Matthew Paulson
Founder and CEO, MarketBeat.
P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.
(ARReply-161)
More Reading from MarketBeat Media 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury NoteBy Chris Markoch. First Published: 10/3/2026. 
Key Points- Rising 10-year Treasury yields, near 5.3% on Sept. 30, have made high-valuation stocks less attractive, prompting a look at dividend alternatives.
- Pfizer, Energy Transfer and Plains All American Pipeline each trade under $30 and offer dividend yields ranging from about 6% to nearly 7%.
- Energy Transfer and Plains All American benefit from midstream oil and gas infrastructure demand, while Pfizer relies on its roughly 95-candidate drug pipeline.
- Special Report: The Last Energy Revolution Starts Now
The 10-year Treasury note yielded around 5.3% in late September. One month earlier, it was around 4.78%, and it's up more than a full percentage point from where it was one year ago.
To put that into perspective, the long-term average yield on the 10-year Treasury note is around 4.25%. However, ever since the financial crisis of 2007 and 2008, investors have become accustomed to much lower long-term rates.
Nvidia has invested more than 7 billion dollars into a light speed device that could reshape how AI systems operate.
Bill Gates put in over 200 million of his own money, while BlackRock, Vanguard, Morgan Stanley and Norway's sovereign wealth fund are positioning around it. Related stocks have already climbed 133 percent, 217 percent and 320 percent.
Wall Street analyst Jason Bodner, who called Nvidia at 4.50, is sharing his top pick tied to this trend at no cost. Click here to see Jason Bodner's free AI stock pick That has been bullish for stocks. Now, however, the opposite is true. Higher long-term bond rates can make high-valuation stocks, or risk-on stocks, less attractive, particularly for investors who are closer to retirement and for whom preserving wealth is more important than generating it.
There is an alternative for investors who still want both growth and income. Many dividend-paying stocks provide exposure to defensive sectors. When combined with the ability to buy shares for under $30 and the opportunity to receive a dividend yield above that of the 10-year Treasury note, this creates an attractive combination for investors.
Pfizer Brings Income and Pipeline OptionalityThe biopharmaceutical trade has been dominated by Eli Lilly (NYSE: LLY), the leader in the rapidly growing GLP-1 industry. Other companies, such as AbbVie (NYSE: ABBV) and Merck & Co. (NYSE: MRK), have deep pipelines in areas such as autoimmune diseases and oncology that appeal to investors. Pfizer (NYSE: PFE) has a diverse pipeline of its own, currently including approximately 95 candidates.
Of course, not all of those drugs will make it through clinical trials. That was the case with its Phase 3 study of the Seagen-derived SV lung cancer therapy, which failed to meet its primary overall-survival endpoint in the overall population.
Pfizer still trades below $30. Shares are up about 14% in 2026, putting the stock roughly in line with its $28.39 consensus price target.
An appealing aspect of PFE for several years has been the company's growing dividend. The company has increased its dividend for 16 consecutive years, with the payout yielding about 6% at recent prices.
Pfizer's revenue is normalizing after surging in 2021 and 2022 because of its COVID-19 vaccine and therapeutics. It only needs a handful of its pipeline candidates to succeed for PFE to deliver on its long-awaited potential.
Energy Transfer Combines Yield With Midstream ScaleHigh oil prices are one of the leading drivers of inflation. However, it's important for investors to understand why. Despite the headline news, there seems to be plenty of oil. The issue is refining that oil and getting it where it needs to go.
That is shifting investor interest in energy stocks away from upstream exploration and production companies and toward midstream companies, which are responsible for transporting oil and natural gas where they need to go.
That brings investors to Energy Transfer (NYSE: ET). The company is a steady stock during a normal cyclical oil cycle. However, many analysts believe this is still the early stage of a long-term bull cycle for oil. Energy Transfer is well positioned to maximize its current pipeline network and strategically add to that network if needed.
ET is up over 20% in 2026, but analysts have a consensus price target of $24.36, which implies more than 20% growth. Plus, the company has a dividend yielding nearly 7%, and Energy Transfer has continued to gradually raise its quarterly payout.
Plains All American Turns Permian Volumes Into IncomeIf Energy Transfer is the diversified midstream play, Plains All American Pipeline (NASDAQ: PAA) is the focused one. The company moves crude oil from the Permian Basin to refiners and export terminals on the Gulf Coast. In May, Plains sold its Canadian natural gas liquids business, leaving it as a near-pure play on crude oil logistics.
Plains is paid mainly based on the volume moving through its system, not the price per barrel. Think of it as a toll road: As long as Permian producers keep drilling, the traffic keeps flowing.
The fundamentals support that view. In its Q2 2026 earnings report, Plains reported adjusted EBITDA of $738 million. Its crude oil segment delivered $690 million, up more than $100 million from the first quarter. Management also raised its outlook for Permian production growth, although it expects most of that benefit to appear in 2027.
PAA trades below $25 and is up approximately 32% in 2026. Analysts are cautious, with a consensus Hold rating and price target of $25.43. That suggests limited upside based on the consensus, although Mizuho recently raised its target to $30.
The real draw is the company's dividend. PAA pays an annual distribution of $1.67, yielding about 7%. The payout has grown for five consecutive years. | 